title: Bevacizumab in the treatment of HER2-negative breast cancer.
abstract: Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Bevacizumab is a potent humanized monoclonal antibody to VEGF, which has shown regression of breast cancer in preclinical and clinical setting, either alone or in combination with cytotoxic treatment. Additionally, bevacizumab potentially increases the effectiveness of other anticancer therapies through the normalization of tumor vasculature, reduction of intratumoral pressure and improved tumor oxygenation. Phase 1/2 trials showed significant antitumor effects of bevacizumab in MBC, in particular in tumors not expressing HER2 receptor. A first phase 3 trial in pre-treated MBC patients showed better response rates but no survival benefit from the addition of bevacizumab to capecitabine. However, in two phase 2 trial in first-line setting in patients with MBC, bevacizumab improved progression-free survival in combination with weekly paclitaxel in comparison to paclitaxel alone or in combination with 3-weekly docetaxel in comparison with docetaxel alone, respectively. Bevacizumab in combination with taxanes seems to be a highly effective first-line treatment for MBC patients. Future research will investigate bevacizumab in the neoadjuvant or adjuvant setting, where even more potential may exist for these patients.
authors.affiliation: Oncologic Institute, Vito Fazzi Hospital, Lecce, Italy.
authors.forename: Vito
authors.initials: V
authors.lastname: Lorusso
references.citation: Anticancer Res. 2007 Jul-Aug;27(4B):2279-87
references.pmid: 17695515
references.citation: J Clin Oncol. 2006 Feb 10;24(5):769-77
references.pmid: 16391297
references.citation: Onkologie. 2007 Dec;30(12):606-8
references.pmid: 18063872
references.citation: Clin Adv Hematol Oncol. 2006 Mar;4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10
references.pmid: 16736568
references.citation: Ann Oncol. 2012 Feb;23(2):331-7
references.pmid: 21821545
references.citation: N Engl J Med. 2007 Dec 27;357(26):2666-76
references.pmid: 18160686
references.citation: Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36
references.pmid: 12457433
references.citation: Endocr Rev. 1997 Feb;18(1):4-25
references.pmid: 9034784
references.citation: Invest New Drugs. 1997;15(1):39-48
references.pmid: 9195288
references.citation: Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24
references.pmid: 14613032
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7135-42
references.pmid: 16192597
references.citation: J Clin Oncol. 2008 Oct 1;26(28):4672-8
references.pmid: 18824714
references.citation: Cancer Res. 1997 Mar 1;57(5):963-9
references.pmid: 9041202
references.citation: Lancet. 1998 Sep 19;352(9132):930-42
references.pmid: 9752815
references.citation: Clin Cancer Res. 2004 Jun 1;10(11):3577-85
references.pmid: 15173063
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1295-311
references.pmid: 15718328
references.citation: Science. 2005 Jan 7;307(5706):58-62
references.pmid: 15637262
references.citation: Cancer. 2005 Oct 15;104(8):1742-50
references.pmid: 16149088
references.citation: Br J Cancer. 1994 Feb;69(2):212-6
references.pmid: 8297716
references.citation: J Clin Oncol. 2001 Feb 1;19(3):843-50
references.pmid: 11157038
references.citation: Ann Oncol. 2002 Jan;13(1):73-80
references.pmid: 11863115
references.citation: Cancer Res. 2001 Apr 15;61(8):3369-72
references.pmid: 11309294
references.citation: J Clin Oncol. 2008 Oct 20;26(30):4899-905
references.pmid: 18794539
references.citation: Cancer Res. 2002 Dec 1;62(23):6938-43
references.pmid: 12460910
references.citation: Int J Oncol. 2005 Mar;26(3):623-8
references.pmid: 15703816
references.citation: Ann Oncol. 2005 Jul;16(7):999-1004
references.pmid: 15939715
references.citation: Nat Rev Cancer. 2004 Jun;4(6):423-36
references.pmid: 15170445
references.citation: J Clin Oncol. 2001 Feb 1;19(3):851-6
references.pmid: 11157039
references.citation: J Clin Oncol. 2005 Feb 1;23(4):792-9
references.pmid: 15681523
references.citation: Clin Breast Cancer. 2008 Aug;8(4):370-3
references.pmid: 18757267
references.citation: Anticancer Res. 1999 Sep-Oct;19(5B):4203-14
references.pmid: 10628376